Circulating tumour-derived predictive biomarkers in oncology

Molecular characterization of tumour material will become increasingly important in selecting patients for clinical trials and offering appropriate treatment for patients in clinical practice. Recent advances in the field have indicated that the molecular characteristics of a tumour can be determine...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2010-02, Vol.15 (3), p.98-101
Main Authors: Hodgson, Darren R., Wellings, Robert, Orr, Maria C.M., McCormack, Rose, Malone, Michael, Board, Ruth E., Cantarini, Mireille V.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biomarkers, Tumor - blood
Colorectal Neoplasms - blood
Colorectal Neoplasms - genetics
DNA, Neoplasm - blood
General pharmacology
Humans
Lung Neoplasms - blood
Lung Neoplasms - genetics
Medical sciences
Neoplasms - blood
Neoplasms - drug therapy
Neoplasms - genetics
Neoplastic Cells, Circulating
Patient Selection
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Molecular characterization of tumour material will become increasingly important in selecting patients for clinical trials and offering appropriate treatment for patients in clinical practice. Recent advances in the field have indicated that the molecular characteristics of a tumour can be determined from circulating tumour cells and circulating tumour DNA; thus, a simple blood sample could provide these data in a simple, convenient and efficient manner. This article discusses progress towards guiding treatment decisions through measuring tumour-derived factors in the circulation.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2009.12.006